![Richard Baxter](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermögen: 182 536 $ am 31.07.2026
Richard B. Baxter is the founder of New Health Capital Partners LLC, founded in 2011, where the title held is Managing Director.
Current jobs include Independent Director at Pelthos Therapeutics, Inc., and Senior Vice President-Investment Operations at Ligand Pharmaceuticals, Inc. Former jobs include Independent Director at Diagnos, Inc. from 2012 to 2014, Managing Director at Fortress Investment Group LLC from 2004 to 2010, Chief Business Officer at Concurrent Pharmaceuticals, Inc., Head-Healthcare Team at Hayfin Capital Management LLP from 2013 to 2017, and Head-Sales, Marketing & Business Development at Viropharma, Inc. Education includes undergraduate studies at Princeton University and an MBA from Harvard Business School.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0,18 % | 15.07.2026 | 6 369 ( 0,18 % ) | 182 536 $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| LIGAND PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 20.02.2024 |
New Health Capital Partners LLC
 New Health Capital Partners LLC Investment ManagersFinance New Health Capital Partners is an active manager which invests in public and private companies located in the United States and Europe. The firm targets companies operating in a broad spectrum of commercial-stage specialty pharmaceutical, medical devices, diagnostics and technology tools companies. They provide financing for senior secured loans and royalty monetization with an investment size ranging from $15 to $100 million and it also takes controlling interest. | Gründer | 01.01.2011 |
| Unternehmen | Position | Ende |
|---|---|---|
Hayfin Capital Management LLP
 Hayfin Capital Management LLP Investment ManagersFinance Operates as an alternative asset management platform that provides debt, equity and hybrid capital solutions | Corporate Officer/Principal | 01.01.2017 |
| DIAGNOS INC. | Direktor/Vorstandsmitglied | 24.07.2014 |
| FORTRESS INVESTMENT GROUP LLC | Direktor/Vorstandsmitglied | 31.12.2010 |
Viropharma, Inc. | Vertrieb & Marketing | - |
Concurrent Pharmaceuticals, Inc.
 Concurrent Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 9 |
|---|---|
Ligand Pharmaceuticals, Inc.
 Ligand Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and sells drug development technologies | Health Technology |
Diagnos, Inc.
 Diagnos, Inc. Information Technology ServicesTechnology Services Provides artificial intelligence services in healthcare sector | Technology Services |
Concurrent Pharmaceuticals, Inc.
Concurrent Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company | Health Technology |
Princeton University
 Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fortress Investment Group LLC
 Fortress Investment Group LLC Investment ManagersFinance Operates as an investment management company | Finance |
Hayfin Capital Management LLP
Hayfin Capital Management LLP Investment ManagersFinance Operates as an alternative asset management platform that provides debt, equity and hybrid capital solutions | Finance |
New Health Capital Partners LLC
New Health Capital Partners LLC Investment ManagersFinance New Health Capital Partners is an active manager which invests in public and private companies located in the United States and Europe. The firm targets companies operating in a broad spectrum of commercial-stage specialty pharmaceutical, medical devices, diagnostics and technology tools companies. They provide financing for senior secured loans and royalty monetization with an investment size ranging from $15 to $100 million and it also takes controlling interest. | Finance |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Viropharma, Inc. |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
